Lates News

According to AI Quick News, Dongwu Securities released a research report on April 28th giving Ma Yinglong (600993.SH) a "buy" rating. The main reasons for the rating include: 1) the pharmaceutical industry is leading with strong performance, stable core hemorrhoid treatment, and accelerated growth in the field of health; 2) optimization of medical services and pharmaceutical business structure, high proportion of dividend payout to shareholders, and long-term value highlights. (Daily Economic News)